APP and Cognitive impairment: APP/PS1 mice expressed a chimeric mouse/human APP with the Swedish double mutations (K595N/M596L) and human presenilin 1 with the exon 9 deletion, developing Aβ deposits as early as 4 months of age and cognitive deficits by 6 months of age.[51, 52] VUF6002 treatment completely reversed their cognitive deficits, as demonstrated in the Y‐Maze (Figure S7C, Supporting Information), NOR (Figure S7D, Supporting Information), and Morris water maze (MWM) (Figure S7E, Supporting Information).